NASDAQ:ONCY Oncolytics Biotech (ONCY) Stock Price, News & Analysis $1.28 +0.03 (+2.40%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Oncolytics Biotech Stock (NASDAQ:ONCY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oncolytics Biotech alerts:Sign Up Key Stats Today's Range$1.25▼$1.3050-Day Range$0.85▼$1.4052-Week Range$0.84▼$1.80Volume450,424 shsAverage Volume320,792 shsMarket Capitalization$97.68 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company OverviewOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Read More… War on Elon Escalates… (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Oncolytics Biotech Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks39th Percentile Overall ScoreONCY MarketRank™: Oncolytics Biotech scored higher than 39% of companies evaluated by MarketBeat, and ranked 727th out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOncolytics Biotech has only been the subject of 1 research reports in the past 90 days.Read more about Oncolytics Biotech's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Oncolytics Biotech are expected to decrease in the coming year, from ($0.29) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -4.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -4.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 4.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oncolytics Biotech's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.34% of the outstanding shares of Oncolytics Biotech have been sold short.Short Interest Ratio / Days to CoverOncolytics Biotech has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncolytics Biotech has recently increased by 48.21%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncolytics Biotech does not currently pay a dividend.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.34% of the outstanding shares of Oncolytics Biotech have been sold short.Short Interest Ratio / Days to CoverOncolytics Biotech has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncolytics Biotech has recently increased by 48.21%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News SentimentN/A News SentimentOncolytics Biotech has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.Search Interest14 people have searched for ONCY on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows3 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by InstitutionsOnly 6.82% of the stock of Oncolytics Biotech is held by institutions.Read more about Oncolytics Biotech's insider trading history. Receive ONCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCY Stock News HeadlinesOncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval PathOctober 4, 2024 | prnewswire.comPromising Progress in Oncology as Cancer Deaths Decline and Research GrowsSeptember 24, 2024 | baystreet.caWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.October 18, 2024 | Porter & Company (Ad)How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for BiotechsSeptember 20, 2024 | tmcnet.comBuy Rating Affirmed on Oncolytics Biotech Following Promising Pelareorep Clinical DataSeptember 20, 2024 | markets.businessinsider.comOncolytics Biotech reports positive results from breast cancer studySeptember 19, 2024 | msn.comOncolytics Biotech Reports Favorable Results For Breast Cancer StudySeptember 19, 2024 | markets.businessinsider.comOncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling StudySeptember 19, 2024 | prnewswire.comSee More Headlines ONCY Stock Analysis - Frequently Asked Questions How have ONCY shares performed this year? Oncolytics Biotech's stock was trading at $1.35 on January 1st, 2024. Since then, ONCY shares have decreased by 5.2% and is now trading at $1.28. View the best growth stocks for 2024 here. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (NASDAQ:ONCY) announced its earnings results on Thursday, August, 1st. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. How do I buy shares of Oncolytics Biotech? Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Meta Platforms (META), Palantir Technologies (PLTR), QUALCOMM (QCOM) and VBI Vaccines (VBIV). Company Calendar Last Earnings8/01/2024Today10/17/2024Next Earnings (Estimated)11/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ONCY CUSIPN/A CIK1129928 Webwww.oncolyticsbiotech.com Phone(403) 670-7377Fax403-283-0858Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+212.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,560,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-114.18% Return on Assets-73.66% Debt Debt-to-Equity RatioN/A Current Ratio4.99 Quick Ratio4.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book4.74Miscellaneous Outstanding Shares76,311,000Free Float76,961,000Market Cap$97.68 million OptionableNot Optionable Beta1.79 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ONCY) was last updated on 10/18/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.